The JAK2/STAT3 pathway is involved in the anti-melanoma effects of atractylenolide I

doi:10.1111/exd.13454

	The JAK2/STAT3 pathway is involved in the anti-melanoma effects of atractylenolide I
	Fu, Xiu-Qiong 1; Chou, Ji-Yao 1; Li, Ting 1; Zhu, Pei-Li 1; Li, Jun-Kui 1; Yin, Cheng-Le 1; Su, Tao 1; Guo, Hui 1; Lee, Kin-Wah 1; Hossen, Muhammad Jahangir 1
刊名	Experimental dermatology
	2018-02
卷号	27 期号:2 页码:201-204
ISSN号	1600-0625
DOI	10.1111/exd.13454
文献子类	Letter
英文摘要	In this study, we aimed to investigate the anti-melanoma effects and the JAK2/STAT3 pathway-related mechanism of action of atractylenolide I in human melanoma cells. Our results showed that atractylenolide I effectively reduced viability, induced apoptosis and inhibited migration of melanoma cells. Meanwhile, atractylenolide I decreased the protein expression levels of phospho-JAK2 and phospho-STAT3, and in turn downregulated the mRNA levels of STAT3-targeted genes, including Bcl-xL, MMP-2 and MMP-9. Furthermore, the cytotoxic effect of atractylenolide I was attenuated in STAT3-overactivated A375 cells. These findings indicate that inhibition of JAK2/STAT3 signalling contributes to the anti-melanoma effects of atractylenolide I.
语种	英语
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/266457]
专题	中国科学院上海药物研究所
作者单位	1.Center for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; 2.Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China
推荐引用方式 GB/T 7714	Fu, Xiu-Qiong,Chou, Ji-Yao,Li, Ting,et al. The JAK2/STAT3 pathway is involved in the anti-melanoma effects of atractylenolide I[J]. Experimental dermatology,2018,27(2):201-204.
APA	Fu, Xiu-Qiong.,Chou, Ji-Yao.,Li, Ting.,Zhu, Pei-Li.,Li, Jun-Kui.,...&Yu, Zhi-Ling.(2018).The JAK2/STAT3 pathway is involved in the anti-melanoma effects of atractylenolide I.Experimental dermatology,27(2),201-204.
MLA	Fu, Xiu-Qiong,et al."The JAK2/STAT3 pathway is involved in the anti-melanoma effects of atractylenolide I".Experimental dermatology 27.2(2018):201-204.